Severe asthma therapy
Recently licensed: A start-up has partnered with us to accelerate the development of a therapy for steroid-resistant asthma.
The technology
This is a treatment for severe, steroid-resistant asthma. It enhances steroid activity by selectively inhibiting signalling pathways downstream of TGFẞ.
Market need
Up to 10 per cent of asthma patients are resistant to inhaled corticosteroids. New drugs to control corticosteroid-resistant severe asthma is a major priority.
Technology status
Known compound PF670462 has achieved target validation. This compound enhances steroid activity, without evidence of autoimmune or cardiac toxicities.
- Contact
- Katrina Sorocos
- katrina.sorocos@unimelb.edu.au
- Phone
- +61 3 8344 1919
Banner image: Animation showing the mechanical activation of TGF-beta protein
First published on 11 June 2020.
Share this article
Research commercialisation opportunitiesResearch Innovation and Commercialisation
Keep reading
-
CCL17
Recently licensed: A company has partnered with us to develop a new pain treatment technology that blocks CCL17 expression.
-
Plasmonic pixel
Partner with us to speed up the adoption of the multispectral plasmonic pixel. Talk to us about licensing or direct investment.
-
Predicting landslides
New open-pit mining technology can predict landslides up to 15 days in advance.
-
Severe asthma therapy
Recently licensed: A start-up has partnered with us to accelerate the development of a therapy for steroid-resistant asthma.